

SmithKline Beecham (Investments) Limited
(Registered Number 302065)

Annual Report and Financial Statements

For the year ended 31st December 2005



Registered office address:

980 Great West Road
Brentford
Middlesex
TW8 9GS

SmithKline Beecham (Investments) Limited
Annual Report and Financial Statements
For the year ended 31st December 2005

	Pages
Directors' Report	1-2
Independent Auditors' Report	3
Profit and Loss Account	4
Balance Sheet	5
Notes to the Financial Statements	6-8

SmithKline Beecham (Investments) Limited

Directors' Report for the year ended 31st December 2005

The Directors submit their report and the audited financial statements for the year ended 31st December 2005.

Principal activities

The Company's principal activity during the year was the receipt of interest on intercompany loans. The Directors do not envisage any change to the nature of the business in the foreseeable future.

Review of business

The Company made a profit on ordinary activities after taxation of £13,928,000 (2004 - £12,537,000). The Directors are of the opinion that the current level of activity and the year end financial position are satisfactory and will remain so in the foreseeable future.

The retained profit for the year of £13,928,000 will be transferred to reserves (2004 - retained profit for the year of £12,537,000 transferred to reserves).

Results and dividends

The Company's results for the financial year are shown in the profit and loss account on page 4.

The Directors propose that no dividend be paid to the holders of Ordinary Shares in respect of the year ended 31st December 2005 (2004 - £nil).

Directors and their interests

The Directors of the Company who served during the year are as follows:

Glaxo Group Limited
Edinburgh Pharmaceutical Industries Limited

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business except where such an interest may arise in the ordinary course of business.

Save as disclosed, no arrangements to which the Company was a party existed at the end of the year, or at any time during the year, which would enable the Directors to acquire benefits through the acquisition of shares, or debentures of the Company, or any body corporate within the GlaxoSmithKline Group (the Group).

At 31st December 2005 none of the Directors have beneficial interests in the shares of any other Group company, except where such a beneficial interest may arise in the ordinary course of business.

Directors' indemnity

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of its duties.

SmithKline Beecham (Investments) Limited

Directors' Report for the year ended 31st December 2005

Statement of Directors' responsibilities

Company law requires the Directors to prepare financial statements for each financial year that give a true and fair view of the state of affairs of the Company and of the profit or loss for that year.

In preparing the financial statements the Directors are required to:

- Select suitable accounting policies and then apply them consistently.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.

The Directors confirm that they have complied with the above requirements in preparing the financial statements.


The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the accounts.

Auditors

Elective resolutions to dispense with holding Annual General Meetings, the laying of accounts before the Company in general meetings and the appointment of Auditors annually are currently in force. The Auditors, PricewaterhouseCoopers LLP, will therefore be deemed to have been reappointed at the end of the period of 28 days beginning with the day on which copies of this Report and Accounts are sent to members unless a resolution is passed under Section 393 of the Companies Act to the effect that their reappointment be brought to an end.

By order of the Board



P Williamson
For and on behalf of Edinburgh Pharmaceutical Industries Limited
Company Secretary
23rd February 2006

SmithKline Beecham (Investments) Limited

Independent auditors' report to the shareholders of SmithKline Beecham (Investments) Limited

We have audited the financial statements of SmithKline Beecham (Investments) Limited for the year ended 31st December 2005 which comprise the Profit and Loss Account, the Balance Sheet, and the related notes. These financial statements have been prepared under the accounting policies set out therein.

Respective responsibilities of directors and auditors

As described in the Statement of Directors' Responsibilities the Company's directors are responsible for the preparation of the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland). This report, including the opinion, has been prepared for and only for the Company's members as a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you if, in our opinion, the Directors' Report is not consistent with the financial statements, if the Company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed.

We read the Directors' Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion


We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the Company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion the financial statements:

- give a true and fair view, in accordance with United Kingdom Generally Accepted Accounting Practice, of the state of the Company's affairs as at 31 December 2005 and of its profit for the year then ended; and
- have been properly prepared in accordance with the Companies Act 1985.



PricewaterhouseCoopers LLP
Chartered Accountants and Registered Auditors
London
23rd February 2006

SmithKline Beecham (Investments) Limited

Profit and Loss Account

For the year ended 31st December 2005

	Notes	2005 £'000	2004 £'000
Other operating expense	2	(6)	(4)
Interest receivable	3	19,903	17,914
Profit on ordinary activities before taxation		19,897	17,910
Taxation	4	(5,969)	(5,373)
Profit on ordinary activities after taxation		13,928	12,537
Retained profit	8	13,928	12,537

The results disclosed above relate entirely to continuing operations.

There is no difference between the profit on ordinary activities before taxation and the retained profit stated above and their historical cost equivalents.

The Company had no recognised gains or losses during the year other than those reflected in the above profit and loss account.

The notes on pages 6 to 8 form part of these financial statements.

SmithKline Beecham (Investments) Limited

Balance Sheet

As at 31st December 2005

	Notes	2005 £'000	2004 £'000
Debtors	5	444,456	424,557
Current assets		444,456	424,557
Creditors: amounts due within one year	6	(35,909)	(29,938)
Net current assets		408,547	394,619
Total assets less current liabilities		408,547	394,619
Capital and reserves			
Called up share capital	7	1,454	1,454
Share premium account	8	333,477	333,477
Profit and loss account	8	73,616	59,688
Equity shareholders' funds	9	408,547	394,619

The accounts on pages 4 to 8 were approved by the Board of Directors on 23rd February 2006 and were signed on its behalf by:



P Ansell

For and on behalf of Edinburgh Pharmaceutical Industries Limited – Director

The notes on pages 6 to 8 form part of these financial statements.

SmithKline Beecham (Investments) Limited

Notes to the Financial Statements for the year ended 31st December 2005

1 Accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below.

(a) Basis of accounting

These financial statements have been prepared using the historical cost convention, and have been drawn up in accordance with UK generally accepted accounting principles and with UK accounting presentation.

(b) Taxation

The Company accounts for taxation which is deferred or accelerated by reason of timing differences which have originated but not reversed by the balance sheet date. Deferred tax assets are only recognised to the extent that they are considered recoverable against future taxable profits.

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences are expected to reverse. Deferred tax liabilities and assets are not discounted.

2 Other operating expense

	2005	2004
	£'000	£'000
The following items have been charged in other operating expense		
Management fee	6	4

The auditors' remuneration has been borne by the Group.

GlaxoSmithKline Services Unlimited provides various services and facilities to the Company including finance and administrative services for which a management fee is charged. That portion of the management fee relating to staff costs can not be separately ascertained.

3 Interest receivable

	2005	2004
	£'000	£'000
Interest income		
On loans with group undertakings	19,903	17,914
	19,903	17,914

4 Taxation

	2005	2004
	£'000	£'000
Taxation charge based on profits for the period		
UK corporation tax at 30% (2004: 30%)	5,969	5,373
	5,969	5,373

There are no items required to reconcile the profit before taxation at the statutory rate of 30% to the current taxation charge. No provision is required for deferred taxation.

5 Debtors

	2005	2004
	£'000	£'000
Amounts due within one year		
Amounts owed by group undertakings	444,456	424,557
	444,456	424,557

SmithKline Beecham (Investments) Limited

Notes to the Financial Statements for the year ended 31st December 2005

6 Creditors

	2005 £'000	2004 £'000
Amounts due within one year		
Amounts owed to group undertakings	29,936	24,561
Taxation	5,973	5,377
	35,909	29,938

7 Called up share capital - equity interests

	2005 Number of shares	2004 Number of shares	2005 £'000	2004 £'000
Authorised				
Ordinary Shares of £1 each	2,000,000	2,000,000	2,000	2,000
Issued and fully paid				
Ordinary Shares of £1 each	1,453,542	1,453,542	1,454	1,454

8 Reserves - equity interests

	Profit & Loss account £'000	Share Premium £'000	Total Reserves £'000
At 1st January 2005	59,688	333,477	393,165
Retained profit for the financial year	13,928	-	13,928
At 31st December 2005	73,616	333,477	407,093

9 Reconciliation of movement in shareholders' funds

	2005 £'000	2004 £'000
Profit for the financial year	13,928	12,537
Net addition to shareholders' funds	13,928	12,537
Opening shareholders' funds	394,619	382,082
Closing shareholders' funds - equity interests	408,547	394,619

10 Directors' remuneration

The Corporate Directors of the Company received no remuneration in respect of their service to the Company (2004 - £nil).

11 Employees

The Company has no employees as all personnel are employed by other Group companies.

SmithKline Beecham (Investments) Limited

Notes to the Financial Statements for the year ended 31st December 2005

12 Cash flow statement

A cash flow statement has been included in the consolidated financial statements of GlaxoSmithKline plc, the ultimate parent undertaking. As a wholly owned subsidiary of the ultimate parent undertaking, advantage has been taken of the exemption afforded by FRS 1 'Cash Flow Statements' (Revised 1996) not to prepare a cash flow statement.

13 Ultimate parent undertaking

GlaxoSmithKline plc, a company registered in England and Wales, is the Company's ultimate parent undertaking. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company, are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from The Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS. The immediate parent undertaking is SmithKline Beecham plc.

14 Related party transactions

As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 8 'Related Party Disclosures' not to disclose any related party transactions within the Group. There are no other related party transactions.